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compared to electron therapy or brachytherapy with moulds 
and flaps. 
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Purpose or Objective: Vaginal cuff brachytherapy with the 
dose prescribed at 0.5 cm depth from the applicator surface 
has been the standard treatment for gynaecological cancer 
patient after histerectomy for years. The implementation of 
computed tomography based (CT-based) plans caused 
changes in the standard approach in our hospital. We 
narrowed the planning target volume (PTV) in order to meet 
our in-house constraints requirement for organs at risk (OARs) 
in some cases. The aim of the study was to analyze doses at 
OARs in real adjusted image-based plans and in standard 0.5 
cm normalized plans. 
 
Material and Methods: Treatment plans of recent, 
consecutive 70 patients treated with high dose rate vaginal 
cuff CT-based brachytherapy were analyzed retrospectively. 
Dose normalization points and optimization methods were 
adjusted whenever standard approach wasn't suitable to 
meet all dose constraints for OARs (adjusted plan - AP). The 
second, standard treatment plan (SP) was created for every 
AP. APs were divided into three groups based on overdosage 
at definite OAR: Bladder Group (B group), Rectum Group (R 
group) and Bladder & Rectum Group (B&R group). Comparison 
of doses at the most exposed 0.1cc (D0.1cc) and 2cc (D2cc) 
of bladder and rectum between AP and SP was made in all 
three groups. 
 
Results: Vaginal cylinders of 10 to 35 mm radius were used. 
For 54% of all 70 cases the standard approach wasn't deemed 
suitable, and the treatment plan was adjusted (SP- 32 cases, 
AP-38 cases). 53% of the APs were assigned to the R group, 
21% to the B group and 26% to the B&R group. Mean values of 
rectum doses in R Group were 96.6% and 112.0% for RD0.1cc 
and 74.4% and 83.6% for RD2cc for AP and SP respectively. 
Mean values of bladder doses in B Group were 97.2% and 
108.0% for BD0.1cc and 79.3% and 86.9% for BD2cc for AP and 
SP respectively. In B&R Group mean values of RD0.1cc were 
93.1% and 108.9% and mean values of RD2cc were 71.8% and 
81.1% for AP and SP respectively, mean values of BD0.1cc 
were 94.4% and 105.9% and mean values of BD2cc were 77.5% 
and 84.4% for AP and SP respectively. The doses are 
presented as a percentage of prescribed dose. Dose 
differences between both plans in all three groups were 
statistically significant. 
 
Conclusion: Standard approach with dose points at 0.5 cm 
from the applicator surface is not suitable for all patients and 
can increase the risk of bladder or rectum complications. CT-
based plan allowing dose evaluation at OARs should be 
practiced on a daily basis. 
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Purpose or Objective: Brachytherapy has recently advanced 
towards personalized planning dosimetry with the 
commercial availability of image-based treatment planning 
systems for Ir-192. This marks an improvement over TG-43 
based planning dosimetry that relies on source specific data 
pre-calculated in a standard sized geometry of homogeneous 
water, hence disregarding patient-specific radiation scatter 
conditions and the radiological differences of tissue or 
applicator materials from water. The aim of this work is to 
perform a comparative study of the effect of these factors in 
Co-60 and Ir-192 HDR brachytherapy. 
 
Material and Methods: Ten clinical cases were studied for 
each of three disease cites considered (gynaecological, 
esophagus and breast). Two treatment plans were prepared 
for each case using the TG-43 option of a commercially 
available system (SagiPlan) with an Ir-192 (Ir2.A85-2) and a 
Co-60 (Co0.A86) HDR source. The plans were exported in 
dicom RT format. Corresponding personalized dosimetry data 
was obtained from Monte Carlo simulation using the MCNP6 
code. Monte Carlo input files were prepared automatically 
from the parsing of information in the dicom RT data using a 
custom software tool (BrachyGuide). Personalized and TG-43 
based dose distributions were compared in the 3D anatomical 
space of each patient using isodose distributions, % dose 
difference maps, Dose Volume Histograms and relevant 
indices of clinical interest. The statistical and clinical 
significance of differences between personalized and TG-43 
based dosimetry in Co-60 HDR brachytherapy was examined, 
and evaluated relative to corresponding results for Ir-192. 
 
Results: Results indicated that the effect of tissue 
heterogeneities and patient specific scatter conditions is less 
for Co-60 than for Ir-192 HDR treatments. In general, Co-60 
and Ir-192 sources of identical shape and construction have 
been found to deliver clinically comparable dose distributions 
despite definite differences in their physical characteristics. 
This is confirmed in terms of personalized dosimetry in this 
study. A lower dose to critical organs close to the target by 
Co-60 sources was observed along with a small increase in the 
overdose volume (V150 to V400). The choice of isotope was 
not found to have an impact on the prescribed dose. 
 
Conclusion: Co-60 may be used as an effective alternative to 
Ir-192 for HDR brachytherapy, producing similar plans of 
equivalent target coverage, but with a logistical benefit and 
without the need for an image based algorithm for 
personalized dosimetry.  
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Purpose or Objective: The dose delivered to the cervix 
HRCTV is often limited by OAR tolerances. A new applicator 
with shields in the anterior and posterior areas of the ovoids 
has been developed to try to reduce OAR doses. The current 
dose calculation formalism (TG43) calculates dose to water 
and does not take into account tissue heterogeneity. The 
Advanced Collapsed cone Engine (ACE) is the Elekta 
implementation of TG186; it models tissue heterogeneity and 
the effect of shielding. 
 
Material and Methods: Eleven patients were selected that 
had received CT/MR planned brachytherapy for cervical 
cancer using Elekta Fletcher tube and ovoids. The HRCTV and 
OARs had been outlined on the MR. For this study the 
applicator library was used to perform a best fit match of the 
shielded CT/MR Fletcher tube and ovoid model with the CT of 
the insertion. The shielded applicators have a slightly 
different geometry compared to the unshielded Fletcher 
applicators. The 25mm shielded ovoids were overlaid on 
35mm standard ovoids and 30mm shielded ovoids were 
overlaid on 40mm standard ovoids.  
The dwell positions, dwell weights and A points were 
maintained from the clinical plan. The plans were calculated 
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with and without shield attenuation using TG43 and were 
calculated with TG186 fixing the dwell times. It was not 
possible to perform a TG186 calculation without the shields 
in place. The TG186 calculation used a HU based mass 
density and all contoured organs were set to ‘female soft 
tissue’ except bladder which was set to ‘water’ to provide 
the chemical composition.  
The HRCTV D90 and D2cc for rectum, bladder, small bowel 
and sigmoid were recorded and EQD2 doses calculated 
assuming 50.4Gy in 28 fractions external beam component. 
 
Results: Table 1 gives the difference in HRCTV D90 and OAR 
D2cc doses between the different dose calculations.  
 
 
 
The combination of shields and TG186 dose calculation 
reduced the rectum D2cc by an average of 15.8% (5.6%-
31.7%) compared to the TG43 dose calculation with no shields 
in place. This equates to a reduction in EQD2 of 4.2Gy 
(0.6Gy-13Gy) and is associated with an average HRCTV EQD2 
reduction of 1Gy. The reduction is due to the physical effect 
of the shielding and the more accurate dose calculation. 
These results show that the effect of the algorithm is the 
largest contributor as TG43 underestimates the effect of the 
shields. 
 
Conclusion: This study demonstrates that using shielded 
applicators has the potential to reduce the rectum D2cc. The 
rectal dose is rarely our dose limiting organ due to the 
routine use of a rectal retractor, however any reduction in 
rectal dose would be beneficial. Two patients in this cohort 
had rectal D2cc doses greater than 70Gy in the clinical plan. 
For these two patients the shielded TG186 plan reduced the 
rectal D2cc dose significantly by 5.7Gy and 13Gy compared to 
the unshielded TG43 plan. Further work is needed to assess 
the TG186 calculation without shields and the effect of 
applicator geometry on the position of OARs. 
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Purpose or Objective: In vivo dosimetry (IVD) measurements 
in HDR brachytherapy (BT) have to be validated by 
performing a quality assurance check of the functionality of 
the dosimeters right after the treatment. Recalibration is 
also usually required due to the high delivered doses per 
fraction involved. The standard procedure using Ir-192 is 
burdensome due to limited availability of the operating 
theater, where the afterloader containing the Ir-192 source is 
located, as well as due to the transport and setup of the 
water equivalent phantom. In this work, a procedure 
involving the use of a certified low dose emitting Sr-90 source 
was proposed to both perform QA and recalibration of MOSkin 
dosimeters right after IVD in HDR Ir-192 BT without the need 
of the BT theater and phantom setup. 
 
Material and Methods: The MOSkin is a type of MOSFET 
detector developed at the Centre of Medical Radiation 
Physics (CMRP) in the University of Wollongong that was 
integrated into present HDR Ir-192 BT procedures for real 
time IVD. The standard MOSkin calibration/verification 
technique employs the Ir-192 source used in HDR procedures, 
in which case the detector is placed into a water equivalent 
phantom, and irradiated three times with a known dose. The 
average of the three measurements is calculated as the 
calibration coefficient. Instead of using Ir-192, in this study 
the use of a certified low dose emitting Sr-90 source was 
investigated. A very small phantom that allows a fixed 
position of the detector in relation to the source was 
established. Three MOSkins were tested at three stages of 
their lifetime, roughly 15 Gy apart. At each one of these 
stages, each MOSkin was calibrated by performing three 
measures both with Sr-90 and Ir-192. The sensitivity ratio of 
the average values obtained with Sr-90 and Ir192 was 
calculated for each measurement. 
 
Results: Both Sr-90 and Ir-192 measurements confirmed a 
small reduction of MOSkin sensitivity with accumulated dose, 
at 1.1% with every 10 Gy, which is proportional to the change 
in threshold voltage of the dosimeter to the first order of 
approximation. The sensitivity ratio of Sr-90 and Ir-192 
measurements remained at a constant value of 9.0±0.2% for 
all three stages of MOSkin life, and among the three 
dosimeters employed in the experiment. 
 
Conclusion: A stable proportional relationship was 
established between the Ir-192 and Sr-90 calibration 
methods, demonstrating that Sr-90 can be used effectively 
for MOSkin recalibration as well as for post treatment 
verification of their functionality after IVD sessions. The 
procedure involving Sr-90 is much more convenient because it 
does not necessitate the use of the BT operating theater and 
can be easily performed everywhere without any particular 
radioprotection requirements. Additionally it is not necessary 
to know the dose delivered by Ir-192 and Sr-90 to MOSkin but 
rather the time of irradiation of the MOSkin on each of them 
respectively, assuming activity changes of Sr-90 are 
negligible.  
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Purpose or Objective: In high-dose rate (HDR) 
brachytherapy, accurate dose delivery is highly dependent on 
the geometrical and temporal source positioning accuracy. In 
this study, we measured the source position and dwell time 
accuracy of the Varian GammaMedplus iX afterloader as well 
as the dead space of a variety of Varian applicators. 
 
Material and Methods: The source position and dwell time 
accuracy were optically measured using Varian’s source step 
viewer and a videocamera. The Perma-Doc phantom was used 
for dosimetric verification of the afterloader’s source 
positioning accuracy. The most distal source position and the 
dead space of the applicators (titanium/stainless steel/ 
plastic needles, titanium Fletcher-type and flexible tube) 
were measured radiographically using kV imaging and 
dosimetrically using EBT3 film. For these measurements an X-
ray marker and the Ir-192 source were successively inserted 
into the applicators, respectively. The distance between the 
external end of the applicators and the center of the most 
distal X-ray marker and the first dwell position on film were 
measured (Fig.1). 
 
Results: The dwell time deviation measured at different 
source positions is <0.1s, and is in accordance with vendor 
specifications. For the most proximal source position, a 
systematic longer dwell time of 0.13s was observed. This 
deviation should be negligible when multiple dwell positions 
are used. Position verification using the source step viewer 
shows deviations of 0.5–1mm (vendor specs: ± 1mm). At the 
most distal position, the source was always retracted by 1 
mm relative to the nominal position to straighten the source 
